Plasma Fractionation Market Trends and Companies
The global plasma fractionation market size was estimated at US$ 32.75 billion in 2023 and is projected to grow to US$ 72.86 billion by 2034, rising at a compound annual growth rate (CAGR) of 7.54% from 2024 to 2034. The rising therapeutic demand for plasma is boosting the plasma fractionation market.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5320
Market Overview
Plasma fractionation is a complex process to separate blood plasma into individual components, predominantly protein which includes clotting factors, albumin, immunoglobulins and fibrinogens, other components are enzymes and antibodies with phenomenal therapeutical values. Plasma fractionation is widely used in pharmaceutical research to treat chronic diseases. The worldwide rising demand for plasma derivatives due to increased immune disease, coagulation disorders and genetic defects is fuelling the market growth.
Plasma Fractionation Market Trends
- In September 2024, Epsilogen, a global leading biotechnology company in London, expanded its financing round by raising $16.4 million to process the development of its immunoglobulin E (IgE) antibodies for cancer treatment. The investment was sourced by the British Patient Capital, the Novartis Venture Fund, Epidarex Capital, the 3B Future Health Fund and ALSA Ventures.
- In June 2024, Biotest, a global company that supplies plasma protein products and biotherapeutic drugs, controlled by Grifols, a globally leading healthcare company, received FDA approval for marketing Yimmugo – a treatment of primary humoral immunodeficiency (PI) in patients 2 years of age or older.
- In July 2024, the Independent Health and Aged Care Pricing Authority announced Activity Based Funding (ABF) for home-delivered subcutaneous immunoglobulin (SCIg) infusion therapy. This therapy is a non-admitted patient service performed by patients at their homes without a healthcare provider.
Plasma Fractionation Market Trends
In September 2024, Epsilogen, a leading biotechnology company based in London, raised $16.4 million in a financing round to advance its development of immunoglobulin E (IgE) antibodies for cancer treatment. The funds were secured from major investors including British Patient Capital, the Novartis Venture Fund, Epidarex Capital, the 3B Future Health Fund, and ALSA Ventures. This investment highlights the growing interest in plasma-based therapies for cancer treatment.
In June 2024, Biotest, a global supplier of plasma protein products and biotherapeutic drugs, which is now controlled by Grifols, a global healthcare leader, received FDA approval for its Yimmugo product. Yimmugo is a treatment for primary humoral immunodeficiency (PI) in patients aged two years and older, marking an important development in the plasma fractionation sector.
In July 2024, the Independent Health and Aged Care Pricing Authority introduced Activity Based Funding (ABF) for home-delivered subcutaneous immunoglobulin (SCIg) infusion therapy. This new service enables patients to administer their therapy at home without the need for healthcare providers, further emphasizing the trend toward decentralized treatments in plasma fractionation.
Chromatography: The Future of Plasma Fractionation
Chromatography-based methods for plasma separation are rapidly gaining traction in the plasma fractionation market. These techniques offer several advantages, including improved purity and the ability to create novel therapeutic products. Plasma contains over 120 different proteins, and when these proteins are carefully separated and concentrated, they can be used to produce life-saving treatments for various conditions like immune deficiencies and bleeding disorders.
Currently, the majority of plasma fractionation technology still relies on the original ethanol-based protocols, primarily used to isolate albumin. However, for the development of new plasma-derived therapeutics, chromatographic techniques are crucial. These techniques can isolate even trace proteins, preserving the integrity of sensitive proteins like coagulation factors, anticoagulants, and protease inhibitors. Ion-exchange chromatography (IEC), in particular, allows proteins to be preserved in their original pH and ionic conditions, ensuring that even fragile proteins remain intact during the fractionation process.
Sepsis Risk: A Major Market Restraint
One of the significant challenges in plasma fractionation is the potential risk of sepsis, a life-threatening condition that can arise from certain plasma protein imbalances. A study published in Science Translational Medicine identified a pattern in the plasma profiles of ICU patients who developed sepsis. Sepsis occurs when the body’s response to infection becomes dysregulated, leading to multiple organ failure. It is a major cause of death, with approximately 50,000 deaths occurring annually in the United Kingdom due to sepsis.
The study involved analyzing plasma samples from 16,000 patients, measuring protein levels through tandem mass spectrometry and liquid chromatography. The results provided a general plasma protein profile, which can help identify patients who are at risk of developing sepsis. This discovery underscores the importance of monitoring plasma protein levels during fractionation processes to minimize the risk of sepsis and other complications in patients receiving plasma-derived therapies.
Top Companies in Plasma Fractionation Market
- Syntegon
- CSL Behring
- Grifols Therapeutics
- Mitsubishi Tanabe
- Octapharma AG
- Hualan Bio
- Kedrion S.p.A
- Takeda Pharmaceutical Company Ltd.
- LFB Group
- Intas Pharmaceuticals Ltd.
- Biotest AG
- Bio Product Laboratory Ltd.
Discover our detailed Table of Contents (TOC) for the Industry, providing a thorough examination of market segments, material, emerging technologies and key trends. Our TOC offers a structured analysis of market dynamics, emerging innovations, and regional dynamics to guide your strategic decisions in this rapidly evolving healthcare field – https://www.towardshealthcare.com/table-of-content/plasma-fractionation-market-sizing
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5320
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
